Business Context and Reporting Period
This Form 8-K, filed by Priveterra Acquisition Corp. on June 29, 2021, reports an equity issuance occurring June 28, 2021. The filing is associated with the company’s planned business combination. The provided metadata identifies AEON Biopharma, Inc., but the filing registrant is Priveterra Acquisition Corp.
Key Financial and Capital Structure Information
- Priveterra had authority to borrow up to $1.5 million under an unsecured convertible promissory note issued to Priveterra Sponsor, LLC on February 15, 2021.
- As of March 31, 2021, the company had borrowed $100,000 under the note.
- The note’s unpaid principal was due on the earlier of February 11, 2023, or the effective date of a business combination.
- The sponsor could convert outstanding amounts into warrants at a conversion price of $1.50 per warrant. Each warrant permits the purchase of one Class A common share at $11.50 per share, subject to specified adjustments.
- No revenue, profit, cash flow, margin, total debt, cash balance, or liquidity metrics are provided in the filing text.
Material Changes and Unusual Items
On June 28, 2021, the sponsor elected to convert $100,000 of outstanding principal into warrants. The company issued warrants described in the filing as purchasing 66,6666 shares of Class A common stock; the stated share count appears internally inconsistent or typographically unclear and should be verified against the filed exhibit or warrant documentation.
The warrants are identified as Working Capital Warrants and are stated to be identical to the private placement warrants issued to the sponsor in connection with the initial public offering. The issuance was made pursuant to the Section 4(a)(2) exemption from Securities Act registration.
Guidance, Outlook, Risks, and Contingencies
- The note proceeds were intended for ongoing expenses reasonably related to the company’s business and the consummation of a business combination.
- The note’s maturity could be accelerated by completion of a business combination.
- The filing provides no operating guidance, financial outlook, or management discussion of business risks.
- Future dilution may result from exercise of the newly issued warrants at $11.50 per share, subject to adjustment provisions.
Investor Verification Items
- Confirm the correct number of shares underlying the warrants, because the filing text states “66,6666,” which is unclear.
- Review the Sponsor Convertible Note and Warrant Agreement for conversion, adjustment, maturity, and exercise provisions.
- Verify the company’s current outstanding borrowings, cash position, and remaining availability under the $1.5 million note.
- Confirm the status and terms of the contemplated business combination and any resulting dilution.